Alisdair Breckenridge

Learn More
The rising cost of pharmaceutical expenditures in many European countries is of concern to governments required to make effective use of health care budgets. Taking a broad perspective that encompasses institutional, political and supranational aspects of pharmaceutical regulation, this book examines approaches used to manage pharmaceutical expenditure(More)
In 1978 the authors established a weekly psychiatric clinic for Indochinese refugees. During the first 20 months, 50 patients were evaluated and treated at the clinic; a Vietnamese psychiatric resident and several native Indochinese mental health counselors bridged the language and cultural barriers between patients and clinic personnel. Most of the(More)
The main decisions concerning the development of new drugs are taken by the drug producer, the prescriber, the drug regulator and the patient. The decisions taken by each party are different, although their aims are similar--to obtain safer and more effective therapy. These proposals are discussed in relation to antihypertensive drug therapy, but the(More)
The United Kingdom voted in a referendum in June 2016 to leave the European Union (EU) after 45 years of membership. Among the many political, social, and scientific consequences are those for the regulation of health care products. No longer will the efficacy, safety, and quality of medicines in the United Kingdom be subject to an EU regulatory framework.(More)
  • 1